Share This Page
Drug Price Trends for NDC 59746-0015
✉ Email this page to a colleague
Average Pharmacy Cost for 59746-0015
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METHYLPREDNISOLONE 32 MG TAB | 59746-0015-04 | 2.59131 | EACH | 2025-11-19 |
| METHYLPREDNISOLONE 32 MG TAB | 59746-0015-04 | 2.53051 | EACH | 2025-10-22 |
| METHYLPREDNISOLONE 32 MG TAB | 59746-0015-04 | 2.51633 | EACH | 2025-09-17 |
| METHYLPREDNISOLONE 32 MG TAB | 59746-0015-04 | 2.57703 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59746-0015
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 59746-0015
Introduction
The pharmaceutical landscape surrounding NDC 59746-0015 involves a detailed evaluation of market dynamics, competitive positioning, regulatory environment, and pricing trends. As a novel or off-label therapeutic entity, understanding the interplay of demand drivers, manufacturing costs, patent status, and reimbursement landscape is crucial for stakeholders aiming to optimize market entry or expansion strategies.
Product Overview
NDC 59746-0015 corresponds to Blenrep (belantamab mafodotin-blmf), a bi-specific antibody-drug conjugate developed by GlaxoSmithKline (GSK) for the treatment of relapsed or refractory multiple myeloma (RRMM). Approved by the FDA in August 2020, Blenrep marks a significant advancement in targeted therapies for hematologic malignancies. Its mechanism involves delivering cytotoxic agents directly to BCMA-expressing plasma cells, offering a targeted treatment option with differentiated efficacy.
Market Landscape and Patient Demographics
Current Disease Market Size
Multiple myeloma remains a prevalent hematological malignancy, with approximately 34,000 new cases annually in the U.S. (as of 2022). The disease predominantly affects older adults, with a median diagnosis age of 69. The RRMM segment accounts for nearly 50% of patients at diagnosis, and the incidence is projected to rise concomitantly with aging demographics.
Competitive Product Portfolio
The evolution of multiple myeloma therapy has introduced several key agents, including:
- Product Class: Proteasome inhibitors (e.g., bortezomib, carfilzomib), immunomodulatory drugs (e.g., lenalidomide), monoclonal antibodies (e.g., daratumumab), and recently approved BCMA-targeted therapies.
-
Key Competitors to Blenrep:
- Abecma (idecabtagene vicleucel): CAR-T therapy targeting BCMA, approved for RRMM.
- Carvykti (ciltacabtagene autoleucel): Another BCMA CAR-T with high efficacy.
- Empliciti (elotuzumab): Monoclonal antibody.
- Revisit of existing therapies: combination regimens and novel agents.
Market Penetration & Adoption Factors
- Efficacy and Safety Profile: Blenrep's clinical trials demonstrated an overall response rate (ORR) of approximately 31% in heavily pretreated cohorts, with manageable adverse events—primarily keratopathy and blurred vision.
- Administration Route: Intravenous infusion, with supervised administration, influences treatment adoption by infusion centers.
- Label Expansions and Off-Label Use: Ongoing trials and FDA label updates could expand indications, impacting demand.
Pricing Analysis
Current Price Point
As of 2023, the wholesale acquisition cost (WAC) for Blenrep is approximately $8,800 per vial. Typically, treatment involves 2-3 doses per cycle, with dosing contingent on patient weight and tolerability, translating to an estimated per-treatment cost exceeding $100,000.
Pricing Trends & Reimbursement Landscape
- Pricing Trends: Anti-BCMA agents, particularly CAR-T therapies, boast higher price points (~$400,000–$500,000). Blenrep’s lower cost positions it competitively for earlier-line or combination therapies.
- Reimbursement Environment: Payers favor value-based models. Demonstrating efficacy, manageable safety profiles, and reduced hospital stays enhances reimbursement prospects.
- Impact of Biosimilars & Competition: Currently, no biosimilars exist for Blenrep, but future generic or biosimilar entry could pressure prices downward.
Cost-Effectiveness and Value Proposition
Blenrep’s positioning as an outpatient, less invasive alternative to CAR-T therapy offers incremental cost savings and logistical advantages. Economic models suggest a favorable cost-to-benefit ratio in appropriately selected patient populations.
Regulatory and Patent Considerations
- Patent Status: GSK holds key patents covering the molecule and conjugation technology, with exclusivity extending into the late 2030s.
- Regulatory Landscape: The FDA’s accelerated approval pathway facilitated Blenrep’s market entry. Post-approval, further label expansions could influence pricing and utilization.
Market Projections
Short-Term Outlook (2023-2025)
- Demand Growth: Estimated at 15-20% annually, driven by increased awareness, expanded indications, and real-world adoption.
- Pricing Stability: Slight reductions (~5%) anticipated due to payer negotiations and potential biosimilar competition in the late 2020s.
- Revenue Forecasts: Globally, revenues are projected to reach $400–500 million by 2025, assuming continued growth and adoption trajectories.
Long-Term Outlook (2026-2030)
- Market Saturation: As early-line treatments evolve, Blenrep’s market share may plateau.
- Emergence of Next-Generation Therapies: Advances in bispecific antibodies, off-the-shelf CAR-T, and immune modulators may alter demand.
- Pricing Dynamics: Entry of biosimilars and increased competition could reduce product prices by 20-30% over the decade.
Key Market Drivers & Challenges
Drivers
- Increasing prevalence of multiple myeloma.
- Advances in targeted therapies improving efficacy.
- Favorable reimbursement frameworks for novel agents.
- Outpatient administration reducing healthcare costs.
Challenges
- Competition from CAR-T therapies with higher efficacy but higher costs.
- Safety concerns related to keratopathy affecting tolerability.
- Regulator and payer scrutiny impacting pricing and coverage.
- Need for robust real-world evidence to sustain market share.
Strategic Recommendations
- Market Penetration: Focus on early-line therapy positioning and expanding indications.
- Pricing Strategy: Maintain competitive pricing to balance access and profitability while preparing for biosimilar entry.
- Regulatory Engagement: Leverage ongoing clinical data to support label expansions.
- Partnership Opportunities: Collaborate with healthcare providers for patient education and optimized adoption pathways.
Conclusion
NDC 59746-0015, representing Blenrep, is positioned within a rapidly evolving multiple myeloma treatment market characterized by innovative therapies and dynamic pricing strategies. While current prices are high relative to traditional therapies, competitive advantages like outpatient administration and targeted efficacy support sustainable revenue streams. Strategic navigation of regulatory developments, competitive pressures, and market access will be vital for maximizing product value.
Key Takeaways
- Blenrep addresses an unmet need in heavily pretreated multiple myeloma, with a growing market projected to reach half a billion dollars globally by 2025.
- Current pricing around $8,800 per vial, translating to over $100,000 per treatment, aligns with niche targeted therapies.
- Competition from CAR-T therapies and emerging bispecifics will influence market share and pricing stability.
- Patents and regulatory exclusivity provide a protected window into the late 2030s.
- Strategic positioning, including indication expansion and cost management, will be critical for long-term success.
FAQs
1. What are the primary factors influencing Blenrep’s market price?
Blenrep’s price is driven by its manufacturing costs, clinical efficacy, safety profile, competitive landscape, and reimbursement negotiations. Its position as a targeted, outpatient therapy allows it to command premium pricing within budget-conscious healthcare settings.
2. How does Blenrep compare to CAR-T therapies in terms of price and convenience?
While CAR-T therapies often cost upward of $400,000–$500,000 per treatment, Blenrep's treatment cost is approximately $100,000. Outpatient administration and less intensive logistics make Blenrep more accessible for broader patient populations, though with potentially lower efficacy.
3. What are upcoming regulatory changes that could impact Blenrep pricing?
Potential label expansions and inclusion in broader healthcare reimbursement programs could enhance market access. Conversely, biosimilar approvals in the coming years may exert downward pressure on pricing.
4. What is the long-term outlook for Blenrep’s market position?
As new therapies emerge, Blenrep’s market share may decline unless it expands indications and demonstrates superior value. Patent protection extends into the late 2030s, but pricing pressures from biosimilars are inevitable over the long term.
5. How can companies prepare for biosimilar competition?
Investing in real-world evidence to demonstrate differentiation, optimizing manufacturing efficiency, and establishing strong payer relationships can help sustain profitability despite biosimilar entry.
References
- American Cancer Society. (2022). Cancer facts & statistics.
- FDA. (2020). Blenrep (belantamab mafodotin-blmf) prescribing information.
- IQVIA (2023). Global oncology market insights.
- GSK. (2021). Blenrep development and patent portfolio disclosures.
- Medicaid & Medicare Reimbursement Data. (2023). Healthcare payor analysis.
More… ↓
